Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
=======================================================================================================================================================================================

* Lingfang Xia
* Jin Peng
* Ge Lou
* Mei Pan
* Qi Zhou
* Wenjing Hu
* Huirong Shi
* Li Wang
* Yunong Gao
* Jianqing Zhu
* Yu Zhang
* Rong Sun
* Xianfeng Zhou
* Quanren Wang
* Xiaohua Wu